Prevention and treatment of esophageal variceal bleeding;A nyelocsovarix-vérzés megelozése és kezelése

Orvosi Hetilap

Volumn 147, Issue 51, 2006, Pages 2455-2463

  Vitális, Zsuzsanna ^a,b   Papp, Mária ^a   Tornai, István ^a   Altorjay, István ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Gasztroenterológiai Tanszék ^*  (Hungary)

Author keywords

Bacterial infection; Liver cirrhosis; Portal hypertension; Treatment; Variceal haemorrhage

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CEFOTAXIME; CIPROFLOXACIN; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FRESH FROZEN PLASMA; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; LOSARTAN; NADOLOL; NITRATE; NORFLOXACIN; OCTREOTIDE; PRAZOSIN; PROPRANOLOL; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TERLIPRESSIN; TIMOLOL; VASOPRESSIN DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BLOOD TRANSFUSION; BLOOD VESSEL TONE; BOLUS INJECTION; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; ENDOSCOPIC THERAPY; ENDOSCOPY; ESOPHAGUS VARICES BLEEDING; EVIDENCE BASED MEDICINE; FOLLOW UP; HEMODYNAMICS; HEMOSTASIS; HEPATIC ENCEPHALOPATHY; HUMAN; LIGATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; PORTAL HYPERTENSION; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SCLEROTHERAPY; SECONDARY PREVENTION; ALGORITHM; ESOPHAGUS VARICES; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; PATHOPHYSIOLOGY; PORTOSYSTEMIC ANASTOMOSIS; RECURRENT DISEASE; SPLANCHNIC BLOOD FLOW;

ALGORITHMS; ANTIBIOTIC PROPHYLAXIS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS, ENDOSCOPIC; HUMANS; HYPERTENSION, PORTAL; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PRIMARY PREVENTION; RECURRENCE; SCLEROTHERAPY; SPLANCHNIC CIRCULATION;

EID: 34249695387     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Abraldes, J. G., Tarantino, I, Turnes, J. és mtsai: Hemodynamic response to pharmacologic treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology, 2003, 37, 902-908.
2. Albillos, A., Lledo, J. L., Rossi, I. és mtsai: Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology, 1995, 109, 1257-1265.
3. Albillos, A., Banares, R., Barrios, C. és mtsai: Oral administration of donidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology, 1992, 102, 248-254.
4. Avgerinos, A., Armonis, A., Stefanidis, G. és mtsai: Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology, 2004, 39, 1623-1630.
5. Baik, S. K., Jeong, P. H., Ji, S. W. és mtsa: Acute hemodynamic effect of octreotide and terlipressin in patients with cirrhosis: A randomized comparison. Am. J. Gastroenterol., 2005, 100, 631-635.
6. Ballet, F., Chrétien, Y., Rey, C. és mtsa: Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused fat liver. J. Pharmacol. Exp. Ther., 1988, 244, 233-235.
7. 1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology, 1999, 30, 79-83.
8. Basili, S., Ferro, D., Leo, R. és mtsai: Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. J. Hepatol., 1996, 24, 574-580.
9. Ben-Ari, Z., Osman, E., Hutton, R. A. és mtsai: Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am. J. Gastroenterol., 1999, 94, 2977-2982.
10. Benoit, J. N., Barrowman, J. A., Harper, S. L. és mtsai: Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am. J. Physiol., 1984, 247, G486-493.
11. Benoit, J. N., Womack, W. A., Hernández, L. és mtsai: "Forward" and "backward" flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis. Gastroenterology, 1985, 89, 1092-1096.
12. Benoit, J. N., Zimmerman, B., Premen, A. J. és mtsai: Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am. J. Physiol., 1986, 251, G674-677.
13. Bosch, J., Garcia-Pagan, J. C.: Complications of cirrhosis. I. Portal hypertension. J. Hepatol., 2000, 32 (Suppl. 1.), 141-156.
14. Bosch, J., Thabut, D., Bendsten, F. és mtsai: Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomised, double-blind trial. Gastroenterology, 2004, 127, 1123-1130.
15. Burroughs, A. K., Vangeli, M.: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand. J. Gastroenterol., 2002, 37, 249-252.
16. Chelarescu, O., Chelarescu, D., Tircoveanu, E. és mtsai: Propranolol administration on post surgical infections in cirrhotic patients. J. Hepatol., 2003, 38 (Suppl. 2.), A173.
17. Cravats, D., Bosch, J., Arterial, M. T. és mtsai: Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am. J. Physiol., 1988, 254, G322-325.
18. D'Amico, G., Pagliaro, L., Bosch, J.: Pharmacological treatment of portal hypertension: an evidence based approach. Semin. Liver Dis., 1999, 19, 475-505.
19. D'Amico, G., Pagliaro, L., Bosch, J.: The treatment of portal hypertension: a meta-analytic review. (Special article). Hepatology, 1995, 22, 332-354.
20. de Franchis, R.: Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol., 2005, 43, 167-176.
21. Fernández, M., Garda-Pagan, J. C., Casadevall, M. és mtsai: Acute and chronic cyclooxygenase blockade in portal hypertensive rats, influence on nitric oxide biosynthesis. Gastroenterology, 1996, 110, 1529-1535.
22. Fiorucci S., Antonelli, E., Brancaleone, V. és mtsai: NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J. Hepatol., 2003, 39, 932-939.
23. Garcia-Pagan, J. C., Fernández, M., Bernadich, C. és mtsai: Effect of continued nitric oxide inhibition on the development of the portal hypertensive syndrorne following portal vein stenosis in the rat. Am. J. Physiol., 1994, 30, G984-990.
24. Garcia-Tsao, G.: Bacterial infections in cirrhosis: treatment and prophylaxis. J. Hepatol., 2005, 42, S85-S92.
25. Garcia-Tsao, G.: Portal hypertension. Curr. Opin. Gastroenterol., 2005, 21, 313-322.
26. Goulis, J., Chau, T. N., Jordan, S. és mtsai: Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut, 1999, 44, 754-758.
27. Graupera, M., Garcia-Pagan, J. C., Titos, E. és mtsa: 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology, 2002, 122, 387-393.
28. Graupera, M., Garcia-Pagan, J. C., Abraldes, J. G. és mtsai: Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology, 2003, 37, 172-181.
29. Groszmann, R. J., Garcia-Tsao, G., Bosch, J. és mtsai: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Eng. J. Med., 2005, 353, 2254-2261.
30. Hoshino, S., Shinoura, S., Akamine, H. és mtsai: Effect of propranolol for the prevention of spontaneous bacterial peritonitis. Am. J. Gastroenterol., 2000, 95, A349.
31. Jalan, R., Stanley, A. J., Redhead, D. N. és mtsai: Shunt insufficiency after transjugular intrahepatic portosystemic stent-shunt: the whens, whys, hows and what should we do about it? Clin. Radiol., 1997, 52, 329-331.
32. Joshi, N. G., Stanley, A. J.: Update on the management of variceal bleeding. Scott. Med. J., 2005, 50, 5-10.
33. Kamath, P. S.: Esophageal variceal bleeding: primary prophylaxis. Clin. Gastroenterol. Hepatol., 2005, 3, 90-93.
34. Laine, L., Cook, D.: Endoscopic ligation compared with sclerotherapy for treatment of esophageal bleeding. A meta-analysis. Ann. Intern Med., 1995, 123, 280-287.
35. Langer, D. A., Shah, V.: Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J. Hepatol., 2006, 44, 209-216.
36. Lebrec, D., Vinel, J. P., Dupas, J. L.: Complications of portal hypertension in adults: a French consensus. Eur. J. Gastroenterol. Hepatol., 2005, 17, 403-410.
37. Mannucci, P. M., Vicente, V., Vianello, L. és mtsai: Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood, 1986, 67, 1148-1153.
38. McCormick, P. A., Dick, R., Panagou, E. B. és mtsai: Emergency transjugular intrahepatic portosystemic stent shunting as salvage treatment for uncontrolled variceal bleeding. Br. J. Surg., 1994, 81, 1324-1327.
39. Merkel, C., Marin, R., Angeli P. és mtsai: Gruppo Triveneto perl'Ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology, 2004, 127, 476-484.
40. Merkel, C., Sacerdoti, D., Bolognesi M. és mtsai: Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insuIficient response to the beta-blocker alone. Hepatology, 1997, 26, 34-39.
41. Moitinho, E. and the Variceal Bleeding Study Group: Randomised controlled trial comparing different schedules of somatostatin in the treatment of acute variceal beeding. Hepatology, 1998, 28, 771.
42. Morales-Ruiz, M., Cejudo-Martin, P., Fernandez-Varo, G. és mtsai: Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology, 2003, 125, 522-531.
43. Papp M., Udvardy M., Vitális, Zs. és mtsai: Gastrooesophagealis varixvérzés - Újdonságok a patofiziológia terén. Orv. Hetil., 2006, 147, 309-314.
44. Rockey, D. C., Weisiger, R. A.: Endothelin induced contractility of stellate cells from normal and cirrhotic fat liver: implications for regulation of portal pressure. Hepatology, 1996, 24, 233-240.
45. Samuel, H., Nardi, M., Karpatkin, M. és mtsai: Differentiation of autoimmune thrombocytopenia frorn thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements. Br. J. Haematol., 1999, 105, 1086-1091.
46. Schneider, A. W., Kalk, J. F., Klein, C. P.: Effect of losartan, an angiotensin II receptor antagonist on portal pressure in cirrhosis. Hepatology, 1999, 29, 334-339.
47. Shah, V, Toruner, M., Haddad, F.: Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology, 1999, 117, 1222-1228.
48. Thomas, S. H., Joh, T., Benoit, J. N.: Role of bile acids in splanchnic hemodynamic response to chronic portal hypertension. Dig. Dis. Sci., 1991, 36, 1243-1248.
49. Tripodi, A., Salerno, F., Chantarangkul, V. és mtsai: Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology, 2005, 41, 553-558.
50. Wright, A. S., Rikkers, L. F.: Current management of portal hypertension. J. Gastrointest. Surg., 2005, 9, 992-1005.
51. Zafra, C., Abraldes, J. G., Turnes, J. és mtsai: Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology, 2004, 126, 749-755.